FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis.

ABSTRACT:

Background

FOLFOX chemotherapy is one of the most commonly used treatments for colorectal cancer (CRC) patients. However, the efficacy and tolerance of FOLFOX therapy varies between patients. The purpose of this study was to explore hub genes associated with primary chemotherapy-resistance and to explore the possible mechanisms involved from non-European patients.

Method

A weighted gene co-expression network was constructed to identify gene modules associated with chemotherapy resistance in mCRC from China.

Results

A Gene Array Chip was used to detect mRNA expression in 11 mCRC patients receiving preoperative FOLFOX chemotherapy. The immune response was associated with chemotherapy-resistance in microarray data. Through the use of WGCNA, we demonstrated that the cruci

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC7078371 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature